Biohaven (Biohaven) Dividend Payout Ratio : 0.00 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Biohaven Dividend Payout Ratio?

Biohaven's dividend payout ratio for the months ended in Mar. 2024 was 0.00.

The historical rank and industry rank for Biohaven's Dividend Payout Ratio or its related term are showing as below:

BHVN's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.455
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-05-15), the Dividend Yield % of Biohaven is 0.00%.

Biohaven's Dividends per Share for the months ended in Mar. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Biohaven Dividend Payout Ratio Historical Data

The historical data trend for Biohaven's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Dividend Payout Ratio Chart

Biohaven Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dividend Payout Ratio

Biohaven Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Dividend Payout Ratio	Get a 7-Day Free Trial								-	-	-	-	-

Competitive Comparison of Biohaven's Dividend Payout Ratio

For the Biotechnology subindustry, Biohaven's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biohaven's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biohaven's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Biohaven's Dividend Payout Ratio falls into.

Biohaven Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Biohaven's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2023 )	/	EPS without NRI (A: Dec. 2023 )
	=	0	/	-5.73
	=	N/A

Biohaven's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	-2.2
	=	N/A

Biohaven (NYSE:BHVN) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Biohaven Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Biohaven's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Biohaven (Biohaven) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biohaven Ltd (NYSE:BHVN) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

215 Church Street, New Haven, CT, USA, 06510

Website

https://www.biohavenpharma.com

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on discovering and developing therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, immunology, and disease-related biology, including rare disorders. Its neuroscience portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7, glutamate receptors, myostatin, and TRP channels. Its products target diseases such as migraine, depression, bipolar, and schizophrenia.

Executives

Irina Antonijevic	director	215 CHURCH STREET, NEW HAVEN CT 06510
John W Childs	director	111 HUNTINGTON AVENUE, SUITE 2900, BOSTON MA 02199
Vlad Coric	director, officer: Chief Executive Officer	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Matthew Buten	officer: Chief Financial Officer	215 CHURCH STREET, NEW HAVEN CT 06510
Gregory Bailey	director	4 A CHESHAM STREET, LONDON X0 SW1X8DT
George C. Clark	officer: VP, Chief Accounting Officer	215 CHURCH STREET, NEW HAVEN CT 06510
Julia P Gregory	director	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Robert J Hugin	director	C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054
Michael Thomas Heffernan	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Kimberly Gentile	officer: SVP, Clinical Operations	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Kishan Mehta	director	540 WEST 49TH STREET, UNIT# PH1N, NEW YORK NY 10019
Biohaven Pharmaceutical Holding Co Ltd.	10 percent owner	215 CHURCH STREET, NEW HAVEN CT 06510
Bruce Car	officer: Chief Scientific Officer	AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139